Axovant Announces First Parkinson’s Disease Gene Therapy R&D Day and Participation in Upcoming September Conferences”

      – Parkinson’s Disease R&D Day to be hosted by Gavin Corcoran, MD, Chief R&D Officer, on October 30th, 2020, with leading movement disorder specialists
NEW YORK and BASEL, Switzerland, Sept. 08, 2020 (GLOBE NEWSWIRE) — Axovant Gene Therapies Ltd (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the company will provide a corporate overview and participate in 1:1 meetings at upcoming virtual investor and patient conferences in September. Additionally, the company announced plans for their 1st Parkinson’s Disease R&D Day with key opinion leaders.Investor and Patient Conference Presentation details:         A live webcast of the presentations will be available in the Events section of Axovant’s website at www.axovant.com. A replay will be available for approximately 30 days following the conference.About Axovant Gene TherapiesAxovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates target GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinson’s disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit www.axovant.com.Contacts:Media & InvestorsParag Meswani
Axovant Gene Therapies Ltd.
(212) 547-2523
[email protected]
[email protected]
Source: Axovant Gene Therapies 

Bay Street News

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search